Status:
RECRUITING
Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis
Lead Sponsor:
Mayo Clinic
Conditions:
Obesity, Morbid
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
It is not known how much improvement in insulin regulated lipolysis (the breakdown of triglycerides) occurs following substantial, sustained weight loss. Researchers will test the effects of inflammat...
Detailed Description
The purpose of this study is to determine whether the adipose inflammatory cell and cytokine content in Class III obesity is related to lipolysis insulin resistance and, if so, whether sustained, subs...
Eligibility Criteria
Inclusion
- BMI 40 - 50 kg/m2.
- Mo active physical illness that would interfere with mobility or weight loss after bariatric surgery
Exclusion
- Type 1 or Type 2 Diabetes diagnosis or fasting plasma glucose ≥126 mg/dL
- Active coronary artery disease
- Participation in structured exercise (\>2 times per week for 30 minutes or longer)
- Smoking
- Medications known to affect adipose tissue metabolism (e.g., beta blockers, corticosteroids)
- Renal insufficiency (serum creatinine \> 1.5mg/dl)
- Chronic active liver disease (Bilirubin \> 17mmol/L, AST \> 144 IU/L, or ALT\>165IU/L)
- Pregnancy or breastfeeding.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03868592
Start Date
August 1 2019
End Date
May 1 2027
Last Update
February 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 559055